Course Overview
Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and registered nurses in cardiology and primary care settings. PCNA’s 2023 pharmacology CE course is designed to meet the clinical practice and recertification needs of these clinicians.
This 2023 curriculum includes a comprehensive approach to pharmacology in:
- Cardiometabolic Treatments for Obesity
- Therapies to Treat Inflammation in Cardiovascular Disease
- Update on Stroke: Tenecteplase (TNK)
- Antiplatelet Therapy in Primary Prevention
Member Cost: $35Non-member Cost: $75
Credits: 2.85 CE contact hours, 3.40 CE pharmacology hours
Learning Objectives
- Cardiometabolic Treatments for Obesity
- Describe the epidemiology, pathophysiology and history of cardiometabolic conditions
- Compare pharmacokinetics of novel and traditional obesity therapeutics which includes patients with Type 2 diabetes (SGLT2is, GLP1s and GIP/GLP-1 agonist)
- Discuss indications for novel weight loss therapies and their cardiac implications
- Explain strategies to overcome barriers to medication access
- Therapies to Treat Inflammation in Cardiovascular Disease
- Review the role of inflammation in cardiovascular risk assessment
- Examine the pathophysiology and pharmacokinetics of inflammation reduction
- Discuss treatment options for inflammatory conditions
- Explore the inter-disciplinary team based care approach to prescribing and monitoring inflammation and cardiovascular pharmacotherapies
- Update on Stroke: Tenecteplase (TNK)
-
- Review research done to support use of Tenecteplase in acute stroke management
- Describe considerations for decreasing door-to-needle time to improve stroke outcomes
- Discuss advantages and contraindications of Tenecteplase use across patient populations
- Explain administration and monitoring of Tenecteplase
- Antiplatelet Therapy in Primary Prevention
- Review the mechanism of action of antiplatelet therapy
- Describe indications for antiplatelet therapy
- Explain risks and benefits of holding the therapy
- Discuss novel antiplatelet therapy options
CE certificate is available upon successful completion of the post-test and program evaluation.
Faculty
- Angela Golden DNP, FNP-C, FAANP, FOMA
- Joe Saseen PharmD, FNLA, CLS,
- Shavonne Williams MN, APRN, ACNS-BC, ANVP-BC, SCRN, CCRN-K
- Erin Michos MD, MHS, FACC, FAHA, FASE, FASPC
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.